Report provides comparative analyses,
forecasts for development to 2018:
Key Questions Answerd:
- What is the value of the Central European generic and innovative drug market?
- What is the value of the generic and innovative drugs market in Poland, in Romania, Slovakia, the Czech Republic, Hungary and Bulgaria? In which of these countries is the market forecast to experience the fastest growth?
- Which companies are making their mark in the manufacture, development and sale of generic and innovative treatments in each of these six Central European countries?
- How do these markets compare in terms of opportunities and regulatory structures?
Generic and innovative drugs market in
Central Europe, comparative analysis, reimbursement policies and development
forecasts for 2014-2018 is a comprehensive guide to the market and all its
conditions and variables. This unique report defines and compares market conditions
and prospects in each country: Poland, Romania, Bulgaria, Slovakia, the Czech
Republic, and Hungary.
This informative publication, prepared by
Publisher’s experienced team of market analysts, provides and compares all the
newest data describing overall market value and specific value and size data
for each segment in each country. It examines recent growth using historical
and offers detailed forecasts for continued expansion to 2018.
A large portion of the report is dedicated to
clarification of regulatory conditions in the generic and innovative drug
segments in each country. The text examines current reimbursement procedures
and predicted modifications to reimbursement lists and offers a market impact
assessment for each. It examines pricing regulations and drug mark up rates,
SPCs (supplemental protection certificates), patent expiry periods and data
exclusivity regulations and provides VAT rates for these medicines in each
market.
This publication also focuses on the leading
companies engaged in the development, manufacture and sale of generic and
innovative drugs in Central Europe. Informative profiles reveal the size,
earnings and product portfolios of these companies, as well as new information
about upcoming events and strategic plans.
Top selling generic and innovative drugs in
each country are listed in the report, and the specific procedures used by each
country to deal with the problems caused by counterfeit preparations are
described and analysed.
Generic and innovative drugs market in
Central Europe, comparative analysis, reimbursement policies and development
forecasts for 2014-2018 is a convenient, accessible and time saving source of
business intelligence for producers of generic and innovative drugs in Poland,
Slovakia, Hungary, Bulgaria, the Czech Republic and Romania. The report aids
users in preparation for corporate market entry, strategic planning, and
product portfolio development and adjustment. It is also a definitive resource
for banking and investment and consulting professionals with interests in this
regional market and in specific areas of the markets in each country.
Users of this document approach business
decision making from a truly informed perspective. Join them – order your copy
today!
Know
more about this report at : http://mrr.cm/Zd9
No comments:
Post a Comment
Note: only a member of this blog may post a comment.